References & Notes

1. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end-stage heart failure. J Card Fail. 2003;9(3):180-187.

2. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report – 2007. J Heart Lung Transplant. 2007;26(8):769-781.

3. American Heart Association. “Heart Transplants: Statistics.” Available at: Accessed April 2010.

4. Dunning J. Artificial heart transplants. Br Med Bull. 1997;53(4):706-718.

5. Rose EA, Gelijns AC, Moskowitz AJ, et al, and Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.

6. “HeartMate® XVE LVAS Fact Sheet.” Available at: Accessed April 2010.

7. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.

8. U.S. Food and Drug Administration. “Device Approvals and Clearances: Thoratec HeartMate II LVAS.” Available at: Accessed April 2010.

9. Miller LW, Pagani FD, Russell SD, et al, and HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-896.

10. “HeartWare® Ventricular Assist System.” Available at: Accessed April 2010.

11. “HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial.” Available at: Accessed April 2010.